PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34605362-5 2021 Characteristics with the greatest influence on preference towards TPO-RA treatments were method of administration (odds ratio (OR) 5.6, 95% confidence interval (CI) 3.2-10.1) and drug-food interactions (OR 3.2, 95% CI 1.8-5.7). Radium 70-72 thyroid peroxidase Homo sapiens 66-69 22740443-10 2012 The fraction of TPO-RA-treated patients who will be treatment-free after 12-24 months of therapy is unknown but likely to be low. Radium 20-22 thyroid peroxidase Homo sapiens 16-19 34547980-7 2021 In the periods before, during and after TPO-RA treatment, oral corticosteroids were the most commonly used therapy (64.4%, 43.4% and 36.1% of patients, respectively); median cumulative doses across each period were 2521.9, 2000.0 and 2277.8 mg. Radium 44-46 thyroid peroxidase Homo sapiens 40-43 24500066-3 2014 This study aimed to evaluate the effect of TPO-RA treatment on platelet function and on the procoagulant state in ITP patients before (ITP-bR) and after responding (ITP-aR) to treatment. Radium 47-49 thyroid peroxidase Homo sapiens 43-46 24725224-4 2014 We aimed to describe the subset of patients in whom transient Tpo-RA therapy may induce a durable response. Radium 66-68 thyroid peroxidase Homo sapiens 62-65 22185370-4 2012 Initial response to TPO-ra defined as platelet counts >30 x 10(9)/l after 4 weeks of treatment was found in 59% of primary ITP patients, 57% of patients with secondary ITP and 40% of patients with non-ITP. Radium 24-26 thyroid peroxidase Homo sapiens 20-23 34605362-7 2021 CONCLUSION: This is the first study to quantify the preference of individuals with ITP towards TPO-RA treatment attributes and demonstrates preference for orally administered treatments, without drug-food interactions. Radium 99-101 thyroid peroxidase Homo sapiens 95-98 34160821-7 2021 As pharmacists are called to counsel patients on TPO-RA use, a deep understanding of potential adverse events and management strategies, as well as appropriate monitoring, will increase the likelihood that patients meet their goals of therapy in the shortest timeframe. Radium 53-55 thyroid peroxidase Homo sapiens 49-52 35371812-13 2022 Regarding TPO-RA treatment for refractory ITP during pregnancy, only six pregnant cases including the present one treated with eltrombopag have been reported so far. Radium 14-16 thyroid peroxidase Homo sapiens 10-13 35007700-3 2022 Patients in the intervention group were required to receive TPO-RA therapy. Radium 64-66 thyroid peroxidase Homo sapiens 60-63 35007700-6 2022 More thromboembolic events were noted in the TPO-RA group than in the control group: 25 compared to 4. Radium 49-51 thyroid peroxidase Homo sapiens 45-48 35007700-10 2022 Our findings indicate there is a non-significant higher chance of thrombosis in ITP patients with TPO-RA treatments versus ITP patients without TPO-RA treatment. Radium 102-104 thyroid peroxidase Homo sapiens 98-101 35007700-10 2022 Our findings indicate there is a non-significant higher chance of thrombosis in ITP patients with TPO-RA treatments versus ITP patients without TPO-RA treatment. Radium 148-150 thyroid peroxidase Homo sapiens 144-147 32281449-8 2021 Treatment failure was observed in 21% TPO-RA-treated patients and 47% control arm patients (RR = 0.42, 95% CI 0.33-0.53) in RCTs during a median follow-up of 13 weeks, and in 29% TPO-RA-treated patients in cohort studies, during a median follow-up of 69 weeks. Radium 42-44 thyroid peroxidase Homo sapiens 38-41 33213987-6 2021 There were indications that TPO-RA treatment enhanced platelet function, with respect to platelet-monocyte aggregates, soluble P-selectin, GPVI expression, and adhesion under flow. Radium 32-34 thyroid peroxidase Homo sapiens 28-31 33789275-3 2021 PATIENTS/METHODS: UK hematologists completed a survey to characterize self-reported practice patterns related to TPO-RA tapering and discontinuation in patients with ITP. Radium 117-119 thyroid peroxidase Homo sapiens 113-116 33789275-9 2021 Individual differences need to be taken into account when considering TPO-RA tapering or discontinuation. Radium 74-76 thyroid peroxidase Homo sapiens 70-73 33789275-10 2021 CONCLUSIONS: Tapering and discontinuation of TPO-RA therapy may be considered for certain patients with ITP. Radium 49-51 thyroid peroxidase Homo sapiens 45-48 32281449-10 2021 RR of WHO grade >=2 bleeding was 0.58 (0.38-0.86) in TPO-RA-treated patients, compared to control arm patients. Radium 57-59 thyroid peroxidase Homo sapiens 53-56 32712041-5 2021 However physician have to keep in mind that thromboembolism rates appear to be higher with TPO-RA treatment in ITP patients at high risk of thrombosis, and that data from "real-life" studies with very long term follow up are not available. Radium 95-97 thyroid peroxidase Homo sapiens 91-94 32814348-5 2020 Median time of Tpo-RA exposure during pregnancy was 4.4 weeks [range: 1-39 weeks]; the indication for starting Tpo-RA was preparation for delivery in 10/17 (58%) pregnancies whereas 4 had chronic refractory symptomatic ITP and 3 were on eltrombopag when the pregnancy started. Radium 19-21 thyroid peroxidase Homo sapiens 15-18 32814348-5 2020 Median time of Tpo-RA exposure during pregnancy was 4.4 weeks [range: 1-39 weeks]; the indication for starting Tpo-RA was preparation for delivery in 10/17 (58%) pregnancies whereas 4 had chronic refractory symptomatic ITP and 3 were on eltrombopag when the pregnancy started. Radium 115-117 thyroid peroxidase Homo sapiens 111-114 30885035-7 2020 Regression analysis revealed that pre-treatment levels of miR-199a-5p and miR-221-3p could help to predict platelet response to TPO-RA-treatment. Radium 132-134 thyroid peroxidase Homo sapiens 128-131 32476083-10 2020 Patients who achieved R within 14 days from the start of TPO-RA administration exhibited a higher 2-year TFR rate, compared with patients who did not (87.5% vs. 48.5%, p = 0.0106). Radium 61-63 thyroid peroxidase Homo sapiens 57-60 32523658-2 2020 Romiplostim is a peptide TPO-RA approved for over a decade to treat adults with ITP but was just recently US Food and Drug Administration approved to manage ITP in children 1 year of age and older who have had an inadequate response to corticosteroids, intravenous immunoglobulin, or splenectomy. Radium 29-31 thyroid peroxidase Homo sapiens 25-28 31280643-7 2020 After both two and six weeks of TPO-RA-treatment, ITP patients had higher MV-associated PS-activity and phospholipid-dependent thrombin generation in plasma than controls. Radium 36-38 thyroid peroxidase Homo sapiens 32-35 30743272-6 2019 The patients with ITP undergoing TPO-RA therapy presented a pro-coagulant profile due to the formation of a more fibrinolysis-resistant clot because of increased plasminogen activator inhibitor-1 (PAI-1) levels. Radium 37-39 thyroid peroxidase Homo sapiens 33-36 30743272-8 2019 Moreover, patients under TPO-RA treatment presented an enhanced pro-coagulant activity associated with microparticles and an increased platelet apoptosis that causes a higher exposure of phosphatidylserine and, consequently, a larger surface for the binding of the prothrombinase complex. Radium 29-31 thyroid peroxidase Homo sapiens 25-28 29215956-2 2019 Previous long-term TPO-RA clinical trials have shown that thrombotic events occurred in 6% of TPO-RA-treated ITP patients. Radium 23-25 thyroid peroxidase Homo sapiens 19-22 29215956-2 2019 Previous long-term TPO-RA clinical trials have shown that thrombotic events occurred in 6% of TPO-RA-treated ITP patients. Radium 23-25 thyroid peroxidase Homo sapiens 94-97 29215956-2 2019 Previous long-term TPO-RA clinical trials have shown that thrombotic events occurred in 6% of TPO-RA-treated ITP patients. Radium 98-100 thyroid peroxidase Homo sapiens 19-22 29215956-2 2019 Previous long-term TPO-RA clinical trials have shown that thrombotic events occurred in 6% of TPO-RA-treated ITP patients. Radium 98-100 thyroid peroxidase Homo sapiens 94-97 29215956-9 2019 Significantly higher levels of F1+2, D-dimer, and PAI-1 were found in ITP patients before TPO-RA treatment and in patients on long-term TPO-RA treatment than in controls. Radium 94-96 thyroid peroxidase Homo sapiens 90-93 29293383-12 2019 During TPO-RA treatment for up to 2 years, this profile was partially reversed while mild BM reticulin fibrosis was still present in the majority of patients. Radium 11-13 thyroid peroxidase Homo sapiens 7-10 28983953-9 2018 We confirm the efficacy of TPO-RA switch; once achieved, response to the 2nd TPO-RA seems durable. Radium 31-33 thyroid peroxidase Homo sapiens 27-30 28983953-9 2018 We confirm the efficacy of TPO-RA switch; once achieved, response to the 2nd TPO-RA seems durable. Radium 31-33 thyroid peroxidase Homo sapiens 77-80 28983953-9 2018 We confirm the efficacy of TPO-RA switch; once achieved, response to the 2nd TPO-RA seems durable. Radium 81-83 thyroid peroxidase Homo sapiens 27-30 28983953-9 2018 We confirm the efficacy of TPO-RA switch; once achieved, response to the 2nd TPO-RA seems durable. Radium 81-83 thyroid peroxidase Homo sapiens 77-80 27991534-4 2016 Moreover, our results indicated that there was a significant reduction in the proportion of patients needing rescue medications in the TPO-RA groups compared with the control groups (RR: 0.50, 95% CI: 0.42-0.59, P = 2.0 x 10-15) and that the rates of any or severe adverse events were similar between the TPO-RA and control regimens (RR: 1.01, 95% CI: 0.92-1.10; RR: 0.74, 95% CI: 0.54-1.01; respectively). Radium 139-141 thyroid peroxidase Homo sapiens 135-138 27991534-4 2016 Moreover, our results indicated that there was a significant reduction in the proportion of patients needing rescue medications in the TPO-RA groups compared with the control groups (RR: 0.50, 95% CI: 0.42-0.59, P = 2.0 x 10-15) and that the rates of any or severe adverse events were similar between the TPO-RA and control regimens (RR: 1.01, 95% CI: 0.92-1.10; RR: 0.74, 95% CI: 0.54-1.01; respectively). Radium 139-141 thyroid peroxidase Homo sapiens 305-308